Frequency and outcomes of STEMI patients presenting between 12 and 24 h after symptom onset: Late-presenting STEMI.
STEMI
late-presenting
percutaneous coronary intervention
Journal
Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions
ISSN: 1522-726X
Titre abrégé: Catheter Cardiovasc Interv
Pays: United States
ID NLM: 100884139
Informations de publication
Date de publication:
01 2023
01 2023
Historique:
revised:
01
11
2022
received:
29
08
2022
accepted:
04
11
2022
pubmed:
25
11
2022
medline:
21
1
2023
entrez:
24
11
2022
Statut:
ppublish
Résumé
To assess the characteristics and prognosis of ST-elevation myocardial infarction (STEMI) patients, presenting between 12 and 24 h after symptom onset, in contemporary regional STEMI systems of care in the United States. Previous observational studies have been inconsistent regarding the benefit of primary percutaneous coronary intervention (PCI) compared with conservative management for late-presenting STEMI patients and the majority of randomized trials are from the fibrinolytic era. Using a two-center registry-based cohort from March 2003 to December 2020, we evaluated the frequency, clinical characteristics, and outcomes of STEMI patients, stratified by symptom onset to balloon time: <3, 3-6, 6-12, and 12-24 h (late presenters). Among 5427 STEMI patients with available symptom onset time, 6.2% were late presenters, which increased to 11% during the early phase of the Covid-19 pandemic. As symptom onset to balloon time increased, patients were more likely to be older, female, and have a history of hypertension and diabetes mellitus. Late presenters with an identifiable culprit lesion were less likely to be revascularized with PCI (96%, 96%, 95%, and 92%; p for trend = 0.004) and had a longer median door-to-balloon time (82, 109, 107, and 117 min; p for trend < 0.001). In-hospital and 1-year death risks were comparable between late and earlier presenters. Despite the unfavorable risk profile and longer door-to-balloon time, clinical outcomes of late presenters were similar to those presenting within 12 h of symptom onset.
Sections du résumé
OBJECTIVES
To assess the characteristics and prognosis of ST-elevation myocardial infarction (STEMI) patients, presenting between 12 and 24 h after symptom onset, in contemporary regional STEMI systems of care in the United States.
BACKGROUND
Previous observational studies have been inconsistent regarding the benefit of primary percutaneous coronary intervention (PCI) compared with conservative management for late-presenting STEMI patients and the majority of randomized trials are from the fibrinolytic era.
METHODS
Using a two-center registry-based cohort from March 2003 to December 2020, we evaluated the frequency, clinical characteristics, and outcomes of STEMI patients, stratified by symptom onset to balloon time: <3, 3-6, 6-12, and 12-24 h (late presenters).
RESULTS
Among 5427 STEMI patients with available symptom onset time, 6.2% were late presenters, which increased to 11% during the early phase of the Covid-19 pandemic. As symptom onset to balloon time increased, patients were more likely to be older, female, and have a history of hypertension and diabetes mellitus. Late presenters with an identifiable culprit lesion were less likely to be revascularized with PCI (96%, 96%, 95%, and 92%; p for trend = 0.004) and had a longer median door-to-balloon time (82, 109, 107, and 117 min; p for trend < 0.001). In-hospital and 1-year death risks were comparable between late and earlier presenters.
CONCLUSION
Despite the unfavorable risk profile and longer door-to-balloon time, clinical outcomes of late presenters were similar to those presenting within 12 h of symptom onset.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1-10Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2022 Wiley Periodicals LLC.
Références
O'Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction. J Am Coll Cardiol. 2013;61(4):e78-e140. doi:10.1016/j.jacc.2012.11.019
Ibanez B, James S, Agewall S, et al. 2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2018;39(2):119-177. doi:10.1093/eurheartj/ehx393
Cannon CP, Gibson CM, Lambrew CT, et al. Relationship of symptom-onset-to-balloon time and door-to-balloon time with mortality in patients undergoing angioplasty for acute myocardial infarction. JAMA. 2000;283(22):2941-2947. doi:10.1001/jama.283.22.2941
de Luca G, Suryapranata H, Ottervanger JP, Antman EM. Time delay to treatment and mortality in primary angioplasty for acute myocardial infarction. Circulation. 2004;109(10):1223-1225. doi:10.1161/01.CIR.0000121424.76486.20
Busk M, Kaltoft A, Nielsen SS, et al. Infarct size and myocardial salvage after primary angioplasty in patients presenting with symptoms for <12 h vs. 12−72 h. Eur Heart J. 2009;30(11):1322-1330. doi:10.1093/eurheartj/ehp113
Gierlotka M, Gasior M, Wilczek K, et al. Reperfusion by primary percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction within 12 to 24 hours of the onset of symptoms (from a prospective national observational study [PL-ACS]. Am J Cardiol. 2011;107(4):501-508. doi:10.1016/j.amjcard.2010.10.008
Cerrato E, Forno D, Ferro S, Chinaglia A. Characteristics, in-hospital management and outcome of late acute ST-elevation myocardial infarction presenters. J Cardiovas Med. 2017;18(8):567-571. doi:10.2459/JCM.0000000000000527
McNair PW, Bilchick KC, Keeley EC. Very late presentation in ST elevation myocardial infarction: predictors and long-term mortality. IJC Heart Vascul. 2019;22:156-159. doi:10.1016/j.ijcha.2019.02.002
Roberto M, Radovanovic D, de Benedetti E, et al. Temporal trends in latecomer STEMI patients: insights from the AMIS plus registry 1997−2017. Revista Española de Cardiología (English Edition). 2020;73(9):741-748. doi:10.1016/j.rec.2019.10.001
Cho KH, Han X, Ahn JH, et al. Long-term outcomes of patients with late presentation of ST-segment elevation myocardial infarction. J Am Coll Cardiol. 2021;77(15):1859-1870. doi:10.1016/j.jacc.2021.02.041
Bouisset F, Gerbaud E, Bataille V, et al. Percutaneous myocardial revascularization in late-presenting patients with STEMI. J Am Coll Cardiol. 2021;78(13):1291-1305. doi:10.1016/j.jacc.2021.07.039
Horie H, Takahashi M, Minai K, et al. Long-term beneficial effect of late reperfusion for acute anterior myocardial infarction with percutaneous transluminal coronary angioplasty. Circulation. 1998;98(22):2377-2382. doi:10.1161/01.CIR.98.22.2377
Schömig A, Mehilli J, Antoniucci D, et al. Mechanical reperfusion in patients with acute myocardial infarction presenting more than 12 hours from symptom onset: a randomized controlled trial. JAMA. 2005;293(23):2865-2872. doi:10.1001/jama.293.23.2865
Hochman JS, Lamas GA, Buller CE, et al. Coronary intervention for persistent occlusion after myocardial infarction. N Engl J Med. 2006;355(23):2395-2407. doi:10.1056/NEJMoa066139
Abbate A, Biondi-Zoccai GGL, Appleton DL, et al. Survival and cardiac remodeling benefits in patients undergoing late percutaneous coronary intervention of the infarct-related artery. J Am Coll Cardiol. 2008;51(9):956-964. doi:10.1016/j.jacc.2007.11.062
Ndrepepa G, Kastrati A, Mehilli J, Antoniucci D, Schömig A. Mechanical reperfusion and long-term mortality in patients with acute myocardial infarction presenting 12 to 48 hours from onset of symptoms. JAMA. 2009;301(5):487-488. doi:10.1001/jama.2009.32
Nepper-Christensen L, Lønborg J, Høfsten DE, et al. Benefit from reperfusion with primary percutaneous coronary intervention beyond 12 hours of symptom duration in patients with ST-segment-elevation myocardial infarction. Cir: Cardiovas Interven. 2018;11(9):e006842. doi:10.1161/CIRCINTERVENTIONS.118.006842
Kastrati A, Coughlan JJ, Ndrepepa G. Primary PCI, late presenting STEMI, and the limits of time. J Am Coll Cardiol. 2021;78(13):1306-1308. doi:10.1016/j.jacc.2021.08.001
Yildiz M, Sharkey S, Aguirre Fv, et al. The midwest ST-elevation myocardial infarction consortium: design and rationale. Cardiovasc Revascul Med. 2021;23:86-90. doi:10.1016/j.carrev.2020.08.019
Larson DM, Duval S, Sharkey SW, et al. Safety and efficacy of a pharmaco-invasive reperfusion strategy in rural ST-elevation myocardial infarction patients with expected delays due to long-distance transfers. Eur Heart J. 2012;33(10):1232-1240. doi:10.1093/eurheartj/ehr403
Garcia S, Albaghdadi MS, Meraj PM, et al. Reduction in ST-segment elevation cardiac catheterization laboratory activations in the United States during COVID-19 pandemic. J Am Coll Cardiol. 2020;75(22):2871-2872. doi:10.1016/j.jacc.2020.04.011
de Luca G, Verdoia M, Cercek M, et al. Impact of COVID-19 pandemic on mechanical reperfusion for patients with STEMI. J Am Coll Cardiol. 2020;76(20):2321-2330. doi:10.1016/j.jacc.2020.09.546
Riley RF, Kereiakes DJ, Mahmud E, Smith TD, Grines C, Henry TD. “Back to the future” for STEMI? JACC: Case Rep. 2020;2(10):1651-1653. doi:10.1016/j.jaccas.2020.07.011
Henry TD, Kereiakes DJ. The direct and indirect effects of the COVID-19 pandemic on cardiovascular disease throughout the world. Eur Heart J. 2022;43(11):1154-1156. doi:10.1093/eurheartj/ehab782
Siudak Z, Dudek D, Grygier M, et al. Interventional cardiology in Poland in 2020-impact of the COVID-19 pandemic. Annual summary report of the association of cardiovascular interventions of the Polish Cardiac Society and Jagiellonian University Medical College*. Adv Inter Cardiol. 2021;17(2):131-134. doi:10.5114/aic.2021.107490
Yildiz M, Wade SR, Henry TD. STEMI care 2021: addressing the knowledge gaps. Am Heart J Plus: Cardiol Res Practice. 2021;11:100044. doi:10.1016/j.ahjo.2021.100044
Koul S, Andell P, Martinsson A, et al. Delay from first medical contact to primary PCI and all-cause mortality: a nationwide study of patients with ST-elevation myocardial infarction. J Am Heart Assoc. 2014;3(2):e000486. doi:10.1161/JAHA.113.000486
Swap CJ, Nagurney JT. Value and limitations of chest pain history in the evaluation of patients with suspected acute coronary syndromes. JAMA. 2005;294(20):2623-2629. doi:10.1001/jama.294.20.2623